These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29374690)

  • 1. MicroRNA Expression in
    Lundberg IV; Wikberg ML; Ljuslinder I; Li X; Myte R; Zingmark C; Löfgren-Burström A; Edin S; Palmqvist R
    Anticancer Res; 2018 Feb; 38(2):677-683. PubMed ID: 29374690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers.
    Choi YW; Song YS; Lee H; Yi K; Kim YB; Suh KW; Lee D
    Medicine (Baltimore); 2016 Apr; 95(15):e3321. PubMed ID: 27082577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
    Weng WH; Leung WH; Pang YJ; Hsu HH
    Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway.
    Nosho K; Igarashi H; Nojima M; Ito M; Maruyama R; Yoshii S; Naito T; Sukawa Y; Mikami M; Sumioka W; Yamamoto E; Kurokawa S; Adachi Y; Takahashi H; Okuda H; Kusumi T; Hosokawa M; Fujita M; Hasegawa T; Okita K; Hirata K; Suzuki H; Yamamoto H; Shinomura Y
    Carcinogenesis; 2014 Apr; 35(4):776-83. PubMed ID: 24242331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.
    Mosakhani N; Lahti L; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S; Sarhadi VK
    Cancer Genet; 2012 Nov; 205(11):545-51. PubMed ID: 23098991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer.
    Takahashi H; Takahashi M; Ohnuma S; Unno M; Yoshino Y; Ouchi K; Takahashi S; Yamada Y; Shimodaira H; Ishioka C
    BMC Cancer; 2017 Nov; 17(1):723. PubMed ID: 29115941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.
    Igarashi H; Kurihara H; Mitsuhashi K; Ito M; Okuda H; Kanno S; Naito T; Yoshii S; Takahashi H; Kusumi T; Hasegawa T; Sukawa Y; Adachi Y; Okita K; Hirata K; Imamura Y; Baba Y; Imai K; Suzuki H; Yamamoto H; Nosho K; Shinomura Y
    Ann Surg Oncol; 2015 Aug; 22(8):2640-8. PubMed ID: 25472647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA profiling differentiates colorectal cancer according to KRAS status.
    Mosakhani N; Sarhadi VK; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S
    Genes Chromosomes Cancer; 2012 Jan; 51(1):1-9. PubMed ID: 21922590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
    Pehserl AM; Ress AL; Stanzer S; Resel M; Karbiener M; Stadelmeyer E; Stiegelbauer V; Gerger A; Mayr C; Scheideler M; Hutterer GC; Bauernhofer T; Kiesslich T; Pichler M
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27916938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential gene expression of chemokines in KRAS and BRAF mutated colorectal cell lines: role of cytokines.
    Khan S; Cameron S; Blaschke M; Moriconi F; Naz N; Amanzada A; Ramadori G; Malik IA
    World J Gastroenterol; 2014 Mar; 20(11):2979-94. PubMed ID: 24659889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miRNAs-Based Molecular Signature for
    Milanesi E; Dobre M; Bucuroiu AI; Herlea V; Manuc TE; Salvi A; De Petro G; Manuc M; Becheanu G
    J Immunol Res; 2020; 2020():4927120. PubMed ID: 32676506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localization of active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer with or without activating BRAF and KRAS mutations.
    Holck S; Bonde J; Pedersen H; Petersen AA; Chaube A; Nielsen HJ; Larsson LI
    Hum Pathol; 2016 Aug; 54():37-46. PubMed ID: 27036313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic mutation in RAS-RAF axis leads to increased expression of GREB1, resulting in tumor proliferation in colorectal cancer.
    Kochi M; Hinoi T; Niitsu H; Miguchi M; Saito Y; Sada H; Sentani K; Sakamoto N; Oue N; Tashiro H; Sotomaru Y; Yasui W; Ohdan H
    Cancer Sci; 2020 Oct; 111(10):3540-3549. PubMed ID: 32629543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
    Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
    Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer.
    Kawada K; Nakamoto Y; Kawada M; Hida K; Matsumoto T; Murakami T; Hasegawa S; Togashi K; Sakai Y
    Clin Cancer Res; 2012 Mar; 18(6):1696-703. PubMed ID: 22282467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.